SpringWorks Therapeutics, Inc.
SWTX · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.48 | -0.19 | -0.33 | 0.33 |
| FCF Yield | -2.08% | -1.33% | -0.67% | -1.89% |
| EV / EBITDA | -40.33 | -32.57 | -40.34 | -63.14 |
| Quality | ||||
| ROIC | -18.96% | -16.63% | -10.74% | -7.97% |
| Gross Margin | 92.81% | 90.98% | 93.22% | 95.89% |
| Cash Conversion Ratio | 0.83 | 0.38 | 0.47 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | 159.70% | 201.51% | 384.54% | 440.39% |
| Free Cash Flow Growth | -93.49% | -122.53% | 70.42% | 32.06% |
| Safety | ||||
| Net Debt / EBITDA | 0.70 | 0.77 | 1.36 | 1.65 |
| Interest Coverage | -80.70 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.28 | 0.54 | 0.34 | 0.32 |
| Cash Conversion Cycle | 9.88 | 34.62 | 64.82 | 30.65 |